

Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after t
Monday, 21 September 2026
Connect your wallet to join the discussion.
No comments yet. Be the first to share your take.